A New Type of Nanogel Carrier based on Mixed Pluronic Loaded with Low-Dose Antitumor Drugs

Abstract

To design a new type of antitumor nanodrug carrier with good biocompatibility, a drug delivery system with a 2.19% drug-loading rate, measured by high-performance liquid chromatography (HPLC), was prepared by membrane hydration using a mixed polymer: Pluronic® F-127, which binds folic acid (FA), Pluronic® F-68 and triptolide (TPL) (FA-F-127/F-68-TPL). As a control, another drug delivery system based on a single polymer (FA-F-127-TPL) with a 1.90% drug-loading rate was prepared by substituting F-68 with F-127. The average particle sizes of FA-F-127/F-68-TPL and FA-F-127-TPL measured by a particle size analyzer were 30.7 nm and 31.6 nm, respectively. Their morphology was observed by atomic force microscopy (AFM). The results showed that FA-F-127-TPL self-assembled into nanomicelles, whereas FA-F-127/F-68-TPL self-assembled into nanogels. An MTT assay showed that a very low concentration of FA-F-127/F-68-TPL or FA-F-127-TPL could significantly inhibit the proliferation of multidrug-resistant (MDR) breast cancer cells (MCF-7/ADR cells) and induce cell death. The effects were signifcantly different from those of free TPL (P < 0.01). Using the fuorescent probe Nile red (Nr) as the drug model, FA-F-127/F-68-Nr nanogels and FA-F-127-Nr nanomicelles were prepared and then incubated with human hepatocarcinoma (HepG2) and MCF-7/ADR cells, and the fluorescence intensity in the cells was measured by a multifunctional microplate reader. The results indicated that both FA-F-127/F-68-Nr and FA-F-127-Nr had sustained release in the cells, but HepG2 and MCF-7/ADR cells exhibited significantly higher endocytosis of FA-F-127/F-68-Nr than that of FA-F-127-Nr (P < 0.01). A nude mice transplanted tumor model was prepared to monitor FA-F-127/F-68-Nr in the tumor tissue and organs by whole-body fluorescent imaging. The results showed that FA-F-127/F-68-Nr targeted tumor tissues. The prepared nanogels had small particle size, were easy to swallow, exhibited slow release property, targeted tumor cells, and could improve the antitumor effects of TPL; hence, they are ideal carriers for low-dose antineoplastic drugs.

Keywords

pluronic / nanogels / nano drug carriers / triptolide

References

[1] Li Y, Maciel D, Rodrigues J, et al. Biodegradable Polymer Nanogels for Drug/Nucleic Acid Delivery[J]. Chemical Reviews, 2015, 115: 8564-8608.

[2] Sina N, Hugh R, Joselito M, et al. Progress Toward Robust Polymer Hydrogels[J]. Australian Journal of Chemistry, 2011, 64: 1007-1025.

[3] Song CK, Balakrishnan P, Shim CK, et al. Enhanced in vitro Cellular Uptake of P-gp Substrate by Poloxamer-modifed Liposomes (PMLs) in MDR Cancer Cells[J]. Journal of Microencapsulation, 2011, 28: 575-581.

[4] Hanke U, May K, Rozehnal V, et al. Commonly Used Nonionic Surfactants Interact Differently with the Human Effux Transporters ABCB1 (p-glycoprotein)and ABCC2 (MRP2)[J]. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76: 260-268.

[5] Li WN, Sun JL, Guan QX, et al. Research Progress of Pluronic as a Drug Delivery System for Reversing Multidrug Resistance of Tumors[J]. Chinese Pharmaceutical Journal, 2016, 51: 1270-1273.

[6] Mu L Q, Hu X B, Hu YY, et al. Advances in the Study of Overcoming Multidrug Resistance in Cancer by Pluronic Block Copolymers[J]. Chinese Journal of Hospital Pharmacy, 2014, 34: 1780-1784.

[7] Joung YK, Jang JY, Choi JH, et al. Heparin-Conjugated Pluronic Nanogels as Multi-Drug Nanocarriers for Combination Chemotherapy-[J]. Molecular Pharmaceutics, 2013, 10: 685-693.

[8] Kim JY, Choi WI, Kim M, et al. Tumor-targeting Nanogel That Can Function Independently for Both Photodynamic and Photothermal Therapy and Its Synergy from the Procedure of PDT Followed by PTT[J]. Journal of Controlled Release, 2013, 171: 113-121.

[9] Nguyen DH, Lee JS, Bae JW, et al. Targeted Doxorubicin Nanotherapy Strongly Suppressing Growth of Multidrug Resistant Tumor in Mice[J]. International Journal of Pharmaceutics, 2015, 495: 329-335.

[10] Merino S, Martín C, Kostarelos K, et al. Nanocomposite Hydrogels: 3D Polymer-Nanoparticle Synergies for On-Demand Drug Delivery[J]. ACS Nano, 2015, 9: 4686-4697.

[11] Ahmed E M. Hydrogel: Preparation, Characterization, and Applications: A Review[J]. Journal of Advanced Research, 2015, 6: 105-121.

[12] Sasaki Y, Akiyoshi K. Nanogel Engineering for New Nanobiomaterials: from Chaperoning Engineering to Biomedical Applications[J]. Chemical Record, 2010, 10: 366-376.

[13] Zhou QY, Zhang ZH, Pan JF, et al. Development of Poloxamers Used as Carriers for New Dosage Forms of Hydrophobic Drugs[J]. Chinese Journal of Modern Applied Pharmacy, 2011, 28: 315-319.

[14] Longmire M, Choyke PL, Kobayashi H. Clearance Properties of Na-no-sized Particles and Molecules as Imaging Agents: Considerations and Caveats[J]. Nanomedicine, 2008, 3: 703-717.

[15] Zhao P, Zheng M, Yue C, et al. Improving Drug Accumulation and Photothermal Efficacy in Tumor Depending on Size of ICG Loaded Lipid-Polymer Nanoparticles[J]. Biomaterials, 2014, 35: 6037-6046.

[16] Perrault SD, Walkey C, Jennings T, et al. Mediating Tumor Targeting Effciency of Nanoparticles Through Design[J]. Nano Letters, 2009, 9: 1909-1915.

[17] Lee H, Fonge H, Hoang B, et al. The Effects of Particle Size and Molecular Targeting on the Intratumoral and Subcellular Distribution of Polymeric Nanoparticles[J]. Molecular Pharmaceutics, 2010, 7: 1195-1208.

[18] Tao Y, Zhang ML, Ma PC, et al. Triptolide Inhibits Proliferation and Induces Apoptosis of Human Melanoma A375 Cells[J]. Asian Pacifc Journal of Cancer Prevention, 2012, 13: 1611-1615.

[19] Li H, Hui L, Xu W, et al. Modulation of P-glycoprotein Expression by Triptolide in Adriamycin-Resistant K562/A02 Cells[J]. Oncology Letters, 2012, 3: 485-489.

[20] Clawson K A, Borja-Cacho D, Antonoff M B, et al. Triptolide and TRAIL Combination Enhances Apoptosis in Cholangiocarcinoma[J]. Journal of Surgical Research, 2010, 163: 244-249.

[21] Johnson SM, Wang X, Evers BM. Triptolide Inhibits Proliferation and Migration of Colon Cancer Cells by Inhibition of Cell Cycle Regulators and Cytokine Receptors[J]. Journal of Surgical Research, 2011, 168: 197-205.

[22] Alakhova D Y, Rapoport N Y, Batrakova E V, et al. Differential Metabolic Responses to Pluronic in MDR and Non-MDR Cells: A Novel Pathway for Chemosensitization of Drug Resistant Cancers[J]. Journal of Controlled Release, 2010, 142: 89-100.

[23] Agarwal R, Jurney P, Raythatha M, et al. Effect of Shape, Size, and Aspect Ratio on Nanoparticle Penetration and Distribution inside Solid Tissues Using 3D Spheroid Models[J]. Advanced Healthcare Materials, 2015, 15: 2269-2280.